News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Most viewed in the last 7 days from JAMA Oncology
Photo taken from JAMA Oncology/LinkedIn
Apr 3, 2024, 06:05

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”

Additional information.
Source: JAMA Oncology/LinkedIn

cancer cell death chemo-immunotherapy JAMA Oncology NSCLC OncoDaily Oncology patients
Insight
Jul 27, 2024, 07:59
What the NCI says about cervical cancer prevention
Blog
Jul 27, 2024, 07:52
Join key opinion leaders at ESMO Preceptorship on Practising Oncology
Blog
Jul 27, 2024, 07:45
David Zaas: Ribbon cutting of new Atrium Health Wake Forest Baptist Medical Plaza Friendly Center in Greensboro
Blog
Jul 27, 2024, 07:36
Rami Manochakian: Excited to kick off the 33 annual Mayo Clinic Hematology/Oncology Reviews 2024
Blog
Jul 27, 2024, 07:24
Advocates for smoke-free sports environments with Loïc Josseran
Blog
Jul 27, 2024, 07:16
David Linehan: A powerful reminder of how fortunate I am to be a part of URMC
Insight
Jul 27, 2024, 07:12
Ramy Sedhom: Summary points from American Cancer Society - CAPC webinar
Blog
Jul 27, 2024, 07:09
European Hematology Association - Final call to submit late posters for the EHA-SFPM Precision Medicine Meeting
Insight
Jul 27, 2024, 07:00
Characterisation of acquired mechanisms of resistance to PARP inhibitors
Blog
Jul 27, 2024, 06:38
The Jimmy Fund - Spotlighting Vinayak Venkataraman this Sarcoma Awareness Month
Opinion
Jul 27, 2024, 04:30
ECO's Emergencies And Crises Network called an extraordinary meeting to address immediate challenges in patient care
Insight
Jul 27, 2024, 04:22
SIOPE's advocacy activities with the newly elected MEPs in the European Parliament